Literature DB >> 17854351

Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease.

Agustín Anastasia1, Gabriel A de Erausquin, José Wojnacki, Daniel H Mascó.   

Abstract

Electroconvulsive shock (ECS) improves motor function in Parkinson's disease. In rats, ECS stimulates the expression of various factors some of which have been proposed to exert neuroprotective actions. We have investigated the effects of ECS on 6-hydroxydopamine (6-OHDA)-injected rats. Three weeks after a unilateral administration of 6-OHDA, 85-95% nigral dopaminergic neurons are lost. Chronic ECS prevented this cell loss, protect the nigrostriatal pathway (assessed by FloroGold retrograde labeling) and reduce motor impairment in 6-OHDA-treated animals. Injection of 6-OHDA caused loss of expression of glial cell-line derived neurotrophic factor (GDNF) in the substantia nigra. Chronic ECS completely prevented this loss of GDNF expression in 6-OHDA-treated animals. We also found that protected dopaminergic neurons co-express GDNF receptor proteins. These results strongly suggest that endogenous changes in GDNF expression may participate in the neuroprotective mechanism of ECS against 6-OHDA induced toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854351     DOI: 10.1111/j.1471-4159.2007.04856.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  3 in total

1.  Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.

Authors:  Agustín Anastasía; Luciana Torre; Gabriel A de Erausquin; Daniel H Mascó
Journal:  J Neurochem       Date:  2009-02-20       Impact factor: 5.372

2.  Effects of two commonly found strains of influenza A virus on developing dopaminergic neurons, in relation to the pathophysiology of schizophrenia.

Authors:  Fernando Landreau; Pablo Galeano; Laura R Caltana; Luis Masciotra; Agustín Chertcoff; A Pontoriero; Elsa Baumeister; Marcela Amoroso; Herminia A Brusco; Mónica I Tous; Vilma L Savy; María del Rosario Lores Arnaiz; Gabriel A de Erausquin
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

Review 3.  GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease.

Authors:  Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo
Journal:  Front Neuroanat       Date:  2015-02-13       Impact factor: 3.856

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.